BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19759053)

  • 1. Aprepitant-associated ifosfamide neurotoxicity.
    Hansen Ho ; Yuen C
    J Oncol Pharm Pract; 2010 Jun; 16(2):137-8. PubMed ID: 19759053
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
    Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
    J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
    Tajino T; Kikuchi S; Yamada H; Takeda A; Konno S
    J Orthop Sci; 2010 Jan; 15(1):104-11. PubMed ID: 20151259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
    Liu YL; Tsai SH; Chang FW; Yu MH
    Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
    Jarkowski A
    Am J Health Syst Pharm; 2008 Dec; 65(23):2229-31. PubMed ID: 19020190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment and prevention of iphosphamide-induced encephalopathy].
    Sunela K; Bärlund M
    Duodecim; 2016; 132(4):314-7. PubMed ID: 27017785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
    Durand JP; Gourmel B; Mir O; Goldwasser F
    Ann Oncol; 2007 Apr; 18(4):808-9. PubMed ID: 17389531
    [No Abstract]   [Full Text] [Related]  

  • 8. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
    Giovanis P; Garna A; Marcante M; Nardi K; Giusto M
    Tumori; 2009; 95(4):545-6. PubMed ID: 19856674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and severity of ifosfamide-induced encephalopathy.
    Rieger C; Fiegl M; Tischer J; Ostermann H; Schiel X
    Anticancer Drugs; 2004 Apr; 15(4):347-50. PubMed ID: 15057138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
    Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
    J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suspected ifosfamide-induced neurotoxicity.
    McVay JI; Wood AM
    Pharmacotherapy; 1999 Dec; 19(12):1450-5. PubMed ID: 10600096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
    Vazirian F; Samadi S; Rahimi H; Sadeghi M; Mohammadpour AH
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):1-6. PubMed ID: 35635561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.
    Snyder M; Gangadhara S; Brohl AS; Ludlow S; Nanjappa S
    Cancer Control; 2017; 24(5):1073274817729070. PubMed ID: 28975823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ifosfamide induced encephalopathy: 15 observations].
    Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
    Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide encephalopathy.
    Ajithkumar T; Parkinson C; Shamshad F; Murray P
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):108-14. PubMed ID: 17355105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.
    Kerdudo C; Orbach D; Sarradet JL; Doz F
    Pediatr Blood Cancer; 2006 Jul; 47(1):100-2. PubMed ID: 16261598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important role of thiamine in preventing ifosfamide-induced encephalopathy.
    Lombardi G; Zustovich F; Nicoletto MO; Donach M; Pastorelli D
    J Oncol Pharm Pract; 2010 Jun; 16(2):135-6. PubMed ID: 19692431
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe ifosfamide-induced neurotoxicity: a case report.
    Ramos Linares S; Breña Atienza J; Cháfer Rudilla M; Ríos Rull P; Cabello Rodríguez A; Merino Alonso J
    Pharm World Sci; 2010 Apr; 32(2):109-11. PubMed ID: 20033290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High-dose ifosfamide in the treatment of patients with soft tissue sarcoma].
    Tiuliandin SA; Liubimova NV; Sidorova NI; Averinova SG; Kashkadaeva AV; Romanova LF; Shiriaev SV; Garin AM
    Vopr Onkol; 1996; 42(6):19-22. PubMed ID: 9123896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of thiamine in managing ifosfamide-induced encephalopathy.
    Hamadani M; Awan F
    J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.